Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Warner Music Group Corp — how do they compare? Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B), while Warner Music Group Corp trades at $28.87 (market cap $14.73B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 8.7× Warner Music Group Corp's market cap, and Warner Music Group Corp pays a 2.84% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Warner Music Group Corp for 96 Days on average.
| VRTX | WMG | |
|---|---|---|
Market Cap | $128.16B | $14.73B |
Volume | 806,603 | 2,404,416 |
Sector | Health | Media |
52-Week High | $557.96 | $34.72 |
52-Week Low | $407.37 | $23.65 |
Typical Hold Time | 120 Days | 96 Days |
Enterprise Value | $122.29B | $19.03B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Warner Music Group (WMG) trades at $28.91, up 4.71% with strong technical momentum and bullish moving average signals. The company delivered Q2 2026 earnings beat with EPS of $0.38 versus $0.34 expected, continuing positive earnings momentum. Recent partnerships with AI music platforms and strategic licensing renewals highlight growth initiatives in the evolving music industry landscape.
WMG presents compelling value with analyst consensus target of $39.50 (36% upside) and strong institutional buying. However, elevated P/E of 22.52 and recent CFO departure pose execution risks. The stock's 92.72% ROE demonstrates exceptional capital efficiency, but investors should monitor AI integration execution and streaming revenue sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
